Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements

Clinical Lung Cancer

Volumn 16, Issue 5, 2015, Pages e83-e89

  Park, Sojung ^a   Park, Tai Sun ^a   Choi, Chang Min ^a   Lee, Dae Ho ^a   Kim, Sang We ^a   Lee, Jung Shin ^a   Kim, Woo Sung ^a   Song, Joon Seon ^a   Lee, Jae Cheol ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Anaplastic lymphoma kinase; Lung cancer; Pemetrexed; Progression free survival

Indexed keywords

CARBOPLATIN; CISPLATIN; CRIZOTINIB; PEMETREXED; PLATINUM; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; PROTEIN P21; PROTEIN TYROSINE KINASE;

ABDOMINAL ABSCESS; ACUTE CHOLECYSTITIS; ADULT; ADVANCED CANCER; ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; INFECTION; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; ONCOGENE; ONCOGENE K RAS; PERITONITIS; PNEUMONIA; PROGRESSION FREE SURVIVAL; RECEPTOR GENE; TREATMENT OUTCOME; TREATMENT RESPONSE; ADENOCARCINOMA; AGED; DISEASE FREE SURVIVAL; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PEMETREXED; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84941413820     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2015.01.003     Document Type: Article

References (33)

1. N. Hanna, F.A. Shepherd, F.V. Fossella, and et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
2. G.V. Scagliotti, P. Parikh, J. von Pawel, and et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
3. B.H. Grønberg, R.M. Bremnes, O. Flotten, and et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 27 2009 3217 3224
4. L. Paz-Ares, F. de Marinis, M. Dediu, and et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial Lancet Oncol 13 2012 247 255
5. L.G. Paz-Ares, F. de Marinis, M. Dediu, and et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer J Clin Oncol 31 2013 2895 2902
6. J.P. Koivunen, C. Mermel, K. Zejnullahu, and et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer Clin Cancer Res 14 2008 4275 4283
7. K. Inamura, K. Takeuchi, Y. Togashi, and et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers J Thorac Oncol 3 2008 13 17
8. Y. Sun, Y. Ren, Z. Fang, and et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases J Clin Oncol 28 2010 4616 4620
9. F.H. Blackhall, S. Peters, L. Bubendorf, and et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project J Clin Oncol 32 2014 2780 2787
10. A. Barreca, E. Lasorsa, L. Riera, and et al. Anaplastic lymphoma kinase in human cancer J Mol Endocrinol 47 2011 R11 R23
11. A.T. Shaw, B.Y. Yeap, M. Mino-Kenudson, and et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253
12. D.W. Wong, E.L. Leung, K.K. So, and et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS Cancer 115 2009 1723 1733
13. D.R. Camidge, S.A. Kono, A. Flacco, and et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment Clin Cancer Res 16 2010 5581 5590
14. A.T. Shaw, D.W. Kim, K. Nakagawa, and et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2013 2385 2394
15. D.R. Camidge, S.A. Kono, X. Lu, and et al. Anaplastic lymphoma kinase gene rearrangements in non-small-cell lung cancer are associated with prolonged progression-free survival on pemetrexed J Thorac Oncol 6 2011 774 780
16. J.O. Lee, T.M. Kim, S.H. Lee, and et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small-cell lung cancer J Thorac Oncol 6 2011 1474 1480
17. A.T. Shaw, A.M. Varghese, B.J. Solomon, and et al. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small-cell lung cancer Ann Oncol 24 2013 59 66
18. E.A. Eisenhauer, P. Therasse, J. Bogaerts, and et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
19. A.T. Shaw, B.Y. Yeap, B.J. Solomon, and et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Lancet Oncol 12 2011 1004 1012
20. A.T. Shaw, D.W. Kim, R. Mehra, and et al. Ceritinib in ALK-rearranged non-small-cell lung cancer N Engl J Med 370 2014 1189 1197
21. L. Friboulet, N. Li, R. Katayama, and et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small-cell lung cancer Cancer Discov 4 2014 662 673
22. National Comprehensive Cancer Network (NCCN) NCCN clinical practice guidelines in oncology. Non-small-cell lung cancer. Version 4. 2015 Available at: http://www.nccn.org 2015 Accessed February 2015
23. B.J. Solomon, T. Mok, D.W. Kim, and et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer N Engl J Med 371 2014 2167 2177
24. T.W. Jang, C.H. Oak, H.K. Chang, S.J. Suo, and M.H. Jung EGFR and KRAS mutations in patients with adenocarcinoma of the lung Korean J Intern Med 24 2009 48 54
25. L. Kim, K.H. Kim, Y.H. Yoon, and et al. Clinicopathologic and molecular characteristics of lung adenocarcinoma arising in young patients J Korean Med Sci 27 2012 1027 1036
26. M.J. Ahn, J. Lee, Y.H. Park, and et al. Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era J Thorac Oncol 5 2010 1185 1196
27. T. Kawaguchi, A. Matsumura, S. Fukai, and et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small-cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases J Thorac Oncol 5 2010 1001 1010
28. S.H. Ou, A. Ziogas, and J.A. Zell Asian ethnicity is a favorable prognostic factor for overall survival in non-small-cell lung cancer (NSCLC) and is independent of smoking status J Thorac Oncol 4 2009 1083 1093
29. G. Scagliotti, N. Hanna, F. Fossella, and et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies Oncologist 14 2009 253 263
30. K. Takezawa, I. Okamoto, W. Okamoto, and et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small-cell lung cancer Br J Cancer 104 2011 1594 1601
31. D. Kasai, H. Ozasa, T. Oguri, and et al. Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma Anticancer Res 33 2013 1935 1940
32. B.H. Grønberg, M. Lund-Iversen, E.H. Strøm, and et al. Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy J Thorac Oncol 8 2013 1255 1264
33. A. Warth, R. Penzel, H. Lindenmaier, and et al. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype Eur Respir J 43 2014 872 883